Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Harilal, Patel"'
Publikováno v:
Frontiers in Nephrology, Vol 4 (2024)
Desidustat is a small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) discovered and developed by Zydus Lifesciences for the treatment of anemia associated with chronic kidney disease (CKD). This review summarizes the precl
Externí odkaz:
https://doaj.org/article/f87f64d3827a4fd490384c885aff0970
Autor:
Bridget E Barber, Melissa Fernandez, Hardik Babubhai Patel, Catalina Barcelo, Stephen D Woolley, Harilal Patel, Stacey Llewellyn, Azrin N Abd-Rahman, Sunil Sharma, Mukul Jain, Ashok Ghoghari, Ilaria Di Resta, Aline Fuchs, Ioanna Deni, Tomas Yeo, Sachel Mok, David A Fidock, Stephan Chalon, Jörg J Möhrle, Deven Parmar, James S McCarthy, Kevinkumar Kansagra
Publikováno v:
The Lancet Infectious Diseases. 22:879-890
Background\ud \ud New antimalarials with novel mechanisms of action are needed to combat the emergence of drug resistance. Triaminopyrimidines comprise a novel antimalarial class identified in a high-throughput screen against asexual blood-stage Plas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::202690c309002f737190fa9311afbfc2
https://doi.org/10.1016/s1473-3099(21)00679-4
https://doi.org/10.1016/s1473-3099(21)00679-4
Autor:
Hardik Patel, Taufik Momin, Kevinkumar Kansagra, Harilal Patel, Chintan Shah, Ajaykumar Barot, Jay Bhavsar, Kuldipsinh Zala, Deven Parmar
Publikováno v:
Clinical pharmacology in drug developmentReferences.
This randomized, single-treatment, 2-sequence study evaluated the food effect on oral bioavailability of desidustat. Healthy adult male and female subjects were enrolled and randomly assigned to receive desidustat 50 mg orally in a fasting state in o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc75e2492b731170db1fa4376dd4875d
https://pubmed.ncbi.nlm.nih.gov/36458679
https://pubmed.ncbi.nlm.nih.gov/36458679
Autor:
Harilal Patel, Nirav Modi, Jaimin Chaudhari, Prakash Patel, Poonam Giri, Hiren Patel, Vrajesh Pandya, Ranjit Desai, Mukul Jain
Publikováno v:
European journal of drug metabolism and pharmacokinetics. 47(5)
Desidustat is a novel prolyl hydroxylase domain (PHD) inhibitor for the treatment of anemia. The objective of this study was to investigate the pharmacokinetics and drug-drug interaction properties of desidustat using in vitro and in vivo nonclinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33ec7029cb88760917b394ad4736c285
https://pubmed.ncbi.nlm.nih.gov/35881329
https://pubmed.ncbi.nlm.nih.gov/35881329
Autor:
Deven Parmar, Sanjeev Kumar Mendiratta, RajendraKumar Verma, Anurag Parihar, Abhishek Gupta, Renuka Munshi, HiraLal Bhalla, Jatin Patel, Ruchir Shah, Prakash Kurmi, Dinesh C. Agarwal, Nitin Sharma, Shuchi Joshi, Shrikant Sharma, Swapnil Bhoge, Avinash Gawande, Pankaj Kalita, Gaurav Chhaya, Kevinkumar Kansagra, Harish Bekkalele, Harilal Patel
Publikováno v:
Clinical Infectious Diseases. 73:e2722-e2728
BackgroundLimited supply, cost and potential for severe adverse effects observed with the blood derived rabies immunoglobulin products has led to search for alternative therapies. This issue has been addressed by developing an anti-rabies monoclonal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55b57410d5d2cd3e4b71f7c732b8c7fb
https://doi.org/10.1093/cid/ciaa779
https://doi.org/10.1093/cid/ciaa779
Autor:
Mukul R. Jain, Deven Parmar, Soma M Pillai, Tariq H Mansuri, Hardik B. Patel, Kevin Kansagra, Nisarg N Nayak, Ashok Ghoghari, Ilaria Di Resta, Jörg J. Möhrle, Harilal Patel
Publikováno v:
Bioanalysis. 13(23)
Aim: ZY-19489 is a new antimalarial drug candidate and selective LC–MS/MS method was established for estimation of ZY-19489 and its metabolite in human plasma. Materials & methods: LLE was employed for extraction, mass spectrometric quantification
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::067efded8426d513672c5d4912e97a34
https://pubmed.ncbi.nlm.nih.gov/34779650
https://pubmed.ncbi.nlm.nih.gov/34779650
Publikováno v:
Drug Metabolism Letters. 13:3-18
Background: The cocktail approach of probing drug metabolizing enzymes, in particular cytochrome P450 (CYP) enzymes, is a cornerstone in clinical pharmacology studies. The first report of the famous “Pittsburg cocktail” has led the way for the av
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::530c231f451cae74d42f3f3d27877981
https://doi.org/10.2174/1872312812666181119154734
https://doi.org/10.2174/1872312812666181119154734
Autor:
Nuggehally R. Srinivas, Harilal Patel, Nirav Modi, Nirmal D. Desai, Krunal Soni, Prakash Patel, Nitin Dobaria
Publikováno v:
Xenobiotica. 49:1202-1208
1. Pharmacokinetic drug-drug interaction (DDI) data is important from a label claim either in combination drug usage or in polypharmacy situation. 2. Eletriptan undergoes first pass related metabolism through CYP3A4 enzyme to form pharmacologically a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f4cee02c5eb50e33569261b88a03c26
https://doi.org/10.1080/00498254.2018.1540805
https://doi.org/10.1080/00498254.2018.1540805
Publikováno v:
Drug Research. 69:245-255
Avibactam, a potent non-β lactam β-lactamase inhibitor, was recently approved in the USA for combination use with ceftazidime, a cephalosporin antibiotic drug. The addition of avibactam potentiates the antimicrobial drug ceftazidime, which otherwis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e90543b58f191a73579bf552cb8b9814
https://doi.org/10.1055/a-0748-5548
https://doi.org/10.1055/a-0748-5548
Autor:
Jogeswar Mohapatra, Sandeep A. Shedage, Poonam Giri, Pravin Kadam, Ranjit C. Desai, Krishnarup Ghoshdastidar, Harilal Patel, Hitesh Bhayani, Brijesh Kumar Srivastava, Nuggehally R. Srinivas, Ankit Patel, Debdutta Bandhyopadhyay, Prakash Patel, Abhijit Chatterjee, Rajesh Sundar, Mukul R. Jain, Laxmikant Gupta, Pankaj R. Patel, Dinesh Patel
Publikováno v:
Cancer Chemotherapy and Pharmacology. 82:635-647
Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme involved in the detection and repair of DNA damage. Studies have shown that inhibition of PARP and Tankyrase (TNKS) has significant antitumor effect in several types of cancers including BRCA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::298c5b629e54798c9df5baf37844c09f
https://doi.org/10.1007/s00280-018-3653-1
https://doi.org/10.1007/s00280-018-3653-1